These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16328102)

  • 1. Population cell life span models for effects of drugs following indirect mechanisms of action.
    Perez-Ruixo JJ; Kimko HC; Chow AT; Piotrovsky V; Krzyzanski W; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):767-93. PubMed ID: 16328102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delay differential equations based models in NONMEM.
    Yan X; Bauer R; Koch G; Schropp J; Perez Ruixo JJ; Krzyzanski W
    J Pharmacokinet Pharmacodyn; 2021 Dec; 48(6):763-802. PubMed ID: 34302262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.
    Krzyzanski W; Perez-Ruixo JJ; Vermeulen A
    J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):349-77. PubMed ID: 18551354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models.
    Krzyzanski W
    J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):179-204. PubMed ID: 21107661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifespan based indirect response models.
    Krzyzanski W; Perez Ruixo JJ
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):109-23. PubMed ID: 22212685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.
    Krzyzanski W; Woo S; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2006 Apr; 33(2):125-66. PubMed ID: 16565883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic models of age-structured cell populations.
    Krzyzanski W
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):573-89. PubMed ID: 26377617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.
    Bauer RJ; Guzy S; Ng C
    AAPS J; 2007 Mar; 9(1):E60-83. PubMed ID: 17408237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of different population pharmacokinetic algorithms.
    Colucci P; Grenier J; Yue CS; Turgeon J; Ducharme MP
    Ther Drug Monit; 2011 Oct; 33(5):583-91. PubMed ID: 21912327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stochastic differential equations in NONMEM: implementation, application, and comparison with ordinary differential equations.
    Tornøe CW; Overgaard RV; Agersø H; Nielsen HA; Madsen H; Jonsson EN
    Pharm Res; 2005 Aug; 22(8):1247-58. PubMed ID: 16078134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME.
    Tornøe CW; Agersø H; Nielsen HA; Madsen H; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Dec; 31(6):441-61. PubMed ID: 16222784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic modeling of the effect of changes in the environment on cellular lifespan and cellular response.
    Freise KJ; Schmidt RL; Widness JA; Veng-Pedersen P
    J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):527-52. PubMed ID: 18937059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model.
    Bazzoli C; Retout S; Mentré F
    Stat Med; 2009 Jun; 28(14):1940-56. PubMed ID: 19266541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
    Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
    Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approaches to handling pharmacodynamic baseline responses.
    Dansirikul C; Silber HE; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):269-83. PubMed ID: 18446428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting FDA's 1995 Guidance on Bioequivalence Establishment of Topical Dermatologic Corticosteroids: New Research Based Recommendations.
    Ozdin D; Sharma N; Lujan-Zilbermann J; Colucci P; Kanfer I; Ducharme MP
    J Pharm Pharm Sci; 2018; 21(1):413-428. PubMed ID: 30407906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models.
    Krzyzanski W; Dmochowski J; Matsushima N; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):635-55. PubMed ID: 16941234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solution and implementation of distributed lifespan models.
    Koch G; Schropp J
    J Pharmacokinet Pharmacodyn; 2013 Dec; 40(6):639-50. PubMed ID: 24178036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Algorithm and R Program for Fitting and Simulation of Pharmacokinetic and Pharmacodynamic Data.
    Li J; Yan K; Hou L; Du X; Zhu P; Zheng L; Zhu C
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):499-518. PubMed ID: 27488206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics.
    Mentré F; Gomeni R
    J Biopharm Stat; 1995 Jul; 5(2):141-58. PubMed ID: 7581424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.